Neurotoxicity induced by targeted therapies in patients treated for metastatic melanoma

Eur J Cancer. 2019 Apr:111:8-11. doi: 10.1016/j.ejca.2019.01.017. Epub 2019 Feb 22.

Authors

C Velter¹, C Libenciuc¹, E Routier¹, C Mateus¹, J Fahmy¹, L Ghoufi¹, O Lambotte², A Not³, C Cauquil³, S Claveau⁴, J Claveau⁴, C Robert⁵

Affiliations

¹ Dermatology Unit, Oncology Department, Gustave Roussy, 94805 Villejuif, France.
² Internal Medicine and Clinical Immunology Department, Bicêtre Hospital, AP-HP, F-94270 Kremlin Bicêtre, France.
³ Neurology Department, Bicêtre Hospital, AP-HP, F-94270 Kremlin Bicêtre, France.
⁴ Dermatology Department, CHU de Québec, Laval University, Québec City, QC, Canada.
⁵ Dermatology Unit, Oncology Department, Gustave Roussy, 94805 Villejuif, France; Paris-Sud University, Kremlin-Bicêtre, France. Electronic address: [email protected].

PMID: 30798086
DOI: 10.1016/j.ejca.2019.01.017

No abstract available

Publication types

Letter

MeSH terms

Aged
Antineoplastic Agents / adverse effects*
Azetidines / adverse effects
Female
Humans
Imidazoles / adverse effects
Male
Melanoma / drug therapy*
Middle Aged
Molecular Targeted Therapy / adverse effects*
Molecular Targeted Therapy / methods
Oximes / adverse effects
Piperidines / adverse effects
Polyneuropathies / chemically induced*
Pyridones / adverse effects
Pyrimidinones / adverse effects
Skin Neoplasms / drug therapy*
Vemurafenib / adverse effects

Substances

Antineoplastic Agents
Azetidines
Imidazoles
Oximes
Piperidines
Pyridones
Pyrimidinones
Vemurafenib
trametinib
cobimetinib
dabrafenib